MAI, M. kansasii, M. marinum

This section focuses on the antimicrobial therapy for infections caused by Mycobacterium avium complex (MAC), Mycobacterium kansasii, and Mycobacterium marinum. These nontuberculous mycobacteria (NTM) require different treatment approaches than M. tuberculosis due to their intrinsic resistance patterns

General Principles

Drug Susceptibility Testing (DST): DST is crucial for guiding treatment decisions for NTM infections, as susceptibility patterns can vary among species and even within species
Combination Therapy: Treatment of NTM infections typically involves a combination of multiple drugs to improve efficacy and prevent the emergence of drug resistance
Prolonged Treatment Duration: Treatment durations for NTM infections are often longer than those for M. tuberculosis infections
Monitoring for Adverse Effects: Anti-NTM drugs can cause a variety of adverse effects, and patients should be closely monitored during treatment
Clinical Response: Clinical response to therapy should be closely monitored, as some NTM infections can be difficult to eradicate

Mycobacterium avium complex (MAC)

Treatment of Pulmonary MAC Disease
- Macrolide-Based Regimen: The cornerstone of treatment is a macrolide antibiotic (clarithromycin or azithromycin) combined with other drugs
- Recommended Regimen
  - Clarithromycin or azithromycin
  - Ethambutol
  - Rifampin or rifabutin
- Treatment Duration: Treatment should continue for at least 12 months after sputum cultures convert to negative
- Intermittent Regimens: Intermittent (e.g., three times per week) regimens may be used in some cases, but daily regimens are generally preferred
- Amikacin or streptomycin: May be added to the initial regimen in patients with severe disease or extensive cavitary lesions
Treatment of Disseminated MAC Disease (in HIV-Infected Patients)
- Macrolide-Based Regimen: Similar to pulmonary MAC disease, treatment is based on a macrolide antibiotic
- Recommended Regimen
  - Clarithromycin or azithromycin
  - Ethambutol
- Rifabutin: Often added as a third drug, especially if the patient is not taking protease inhibitors
- Treatment Duration: Treatment should continue for at least 12 months, and secondary prophylaxis (maintenance therapy) is recommended for patients with advanced HIV infection
- Immune Reconstitution Inflammatory Syndrome (IRIS): Patients starting antiretroviral therapy (ART) may develop IRIS, an inflammatory response to the mycobacteria. Management may involve corticosteroids or temporary discontinuation of ART
Drug Susceptibility Testing: DST should be performed on all MAC isolates to guide treatment decisions. Macrolide resistance is common and can significantly impact treatment outcomes

Mycobacterium kansasii

Treatment Regimen
- Rifampin-Based Regimen: M. kansasii is generally susceptible to rifampin, making it a key component of the treatment regimen
- Recommended Regimen
  - Isoniazid (INH)
  - Rifampin
  - Ethambutol
- Treatment Duration: Treatment should continue for at least 12 months after sputum cultures convert to negative
- Alternative Drugs: In cases of drug resistance or intolerance, alternative drugs such as clarithromycin, moxifloxacin, or streptomycin may be considered
Drug Susceptibility Testing: DST should be performed to confirm rifampin susceptibility and guide treatment decisions
Monitoring: Patients should be monitored for adverse effects of INH, rifampin, and ethambutol

Mycobacterium marinum

Treatment Regimen
- Localized Skin Infections: Mild, localized infections may respond to topical antibiotics or local wound care
- Oral Antibiotics: More extensive or severe infections typically require oral antibiotics
- Recommended Drugs
  - Tetracyclines (e.g., doxycycline, minocycline)
  - Macrolides (e.g., clarithromycin, azithromycin)
  - Fluoroquinolones (e.g., ciprofloxacin, levofloxacin)
  - Rifampin
  - Ethambutol
  - Trimethoprim/sulfamethoxazole (TMP/SMX)
- Combination Therapy: Combination therapy may be necessary for severe or refractory infections
- Treatment Duration: Treatment duration varies depending on the severity of the infection and the clinical response, but typically ranges from 3-6 months
Drug Susceptibility Testing: DST is not routinely performed for M. marinum infections, as susceptibility patterns are generally predictable
Surgical Excision: In some cases, surgical excision of infected tissue may be necessary
Temperature Sensitivity: M. marinum grows best at lower temperatures (30-32°C), so keeping the affected area warm may inhibit bacterial growth

Key Terms

NTM (Nontuberculous Mycobacteria): Mycobacteria species other than Mycobacterium tuberculosis and Mycobacterium leprae
Macrolides: A class of antibiotics that includes clarithromycin and azithromycin
Rifampin: A broad-spectrum antibiotic used to treat various bacterial infections, including mycobacterial infections
Ethambutol: An antibiotic used in combination with other drugs to treat TB and NTM infections
DST (Drug Susceptibility Testing): A laboratory test to determine the susceptibility of an organism to antimicrobial drugs
Sputum Conversion: The point at which sputum cultures become negative for the presence of mycobacteria
Intermittent Regimen: A treatment regimen in which drugs are administered less frequently than daily
Disseminated Disease: An infection that has spread from a localized area to other parts of the body
HIV (Human Immunodeficiency Virus): A virus that attacks the immune system, leading to AIDS
ART (Antiretroviral Therapy): Treatment for HIV infection that involves a combination of drugs to suppress the virus
IRIS (Immune Reconstitution Inflammatory Syndrome): An inflammatory response that can occur in HIV-infected patients starting ART
Protease Inhibitors: A class of antiretroviral drugs used to treat HIV infection
Refractory Infections: Infections that do not respond to standard treatment
Tetracyclines: A class of antibiotics that includes doxycycline and minocycline
Fluoroquinolones: A class of antibiotics that includes ciprofloxacin and levofloxacin
Trimethoprim/Sulfamethoxazole (TMP/SMX): A combination antibiotic used to treat various bacterial infections
Topical Antibiotics: Antibiotics that are applied directly to the skin or other affected area
Wound Care: Measures taken to clean and protect wounds from infection
Intrinsic Resistance: Resistance to certain antibiotics that is inherent to a particular species of bacteria
Cavity Lesions: An abnormal area in the lung that has been destroyed and replaced by air
Secondary Prophylaxis: Maintenance therapy to prevent recurrence of an infection
Localized Infections: Infections that are confined to a specific area of the body
Aminoglycosides: A class of antibiotics that includes amikacin, kanamycin, and streptomycin

M. tuberculosis

Rapid Growers